To gain more insight into the cellular mechanisms mediating BFA toxicity, we conducted a genome-wide haploid genetic screen that led to the identification of the small G protein ADP-ribosylation factor 4 (ARF4). ARF4 depletion preserves viability, Golgi integrity and cargo trafficking in the presence of BFA, and these effects depend on the guanine nucleotide exchange factor GBF1 and other ARF isoforms including ARF1 and ARF5. ARF4 knockdown cells show increased resistance to several human pathogens including Chlamydia trachomatis and Shigella flexneri. Furthermore, ARF4 expression is induced when cells are exposed to several Golgi-disturbing agents and requires the CREB3 (also known as Luman or LZIP) transcription factor, whose downregulation mimics ARF4 loss. Thus, we have uncovered a CREB3-ARF4 signalling cascade that may be part of a Golgi stress response set in motion by stimuli compromising Golgi capacity.
The processing, sorting and transport of proteins and lipids in the Golgi to their destined intracellular site of action is of fundamental importance to the maintenance and functions of subcellular compartments. The Golgi fulfils several other functions beyond regulation of vesicular transport of cargo such as serving as an important signalling platform where different stimuli converge and by bringing multiple factors together [1] [2] [3] . Moreover, correct Golgi positioning is essential for several directed cell movements including wound healing, secretion or maintenance of cell polarity 4, 5 . BFA was first described as a molecule with antiviral, antibiotic and antifungal activity and is used as pharmacological tool to interrogate vesicular transport processes 6 . BFA also showed anticancer effects against several human tumour cell lines and was explored as a chemotherapeutic compound [7] [8] [9] [10] . BFA treatment of cells inhibits endoplasmic reticulum (ER)-Golgi transport, impedes protein secretion and disperses the Golgi.
The ADP-ribosylation factors (ARFs) are evolutionarily conserved and ubiquitously expressed guanosine triphosphatases (GTPases), which belong to the Ras superfamily of small G proteins. They fulfil critical roles in the secretory pathway for transport of cargo between the ER and Golgi or between different Golgi cisternae and in the endocytic system by recruiting coat proteins, activating lipid-modifying enzymes, and by regulating the cytoskeleton dynamics 11, 12 . The effects of BFA are largely ascribed to the inhibition of ARF small G protein-guanine nucleotide exchange factor (GEF) complexes. BFA acts as an uncompetitive inhibitor by binding in a hydrophobic cavity formed between ARF-GDP and a subset of GEFs, thereby trapping the interaction partners in an unproductive conformation, which prevents exchange of GDP for GTP (ref. 13 ). The BFA-sensitive group of large GEFs includes GBF1, BIG1 and BIG2, which exert their functions at distinct sites throughout the Golgi complex.
Although there is a substantial degree of sequence homology between different ARFs, the family of five small ARF G proteins found in humans is further divided into three classes based on amino acid similarity: class I is composed of ARF1 and ARF3, ARF4 and ARF5 belong to class II, and class III contains a sole member, ARF6. A further distinctive feature is their subcellular localization. With the exception of ARF6, the most distantly related ARF that is present at the plasma membrane and on endosomes 14, 15 , the other ARFs mainly localize at the ER-Golgi interface, with ARF1, 4 and 5 found predominantly at the early Golgi and ERGIC and ARF3 at the trans-Golgi and trans-Golgi network. ARFs also differ in their abundance; for example, ARF1 and ARF3 are expressed at 3-10-fold higher levels than ARF4-6 (ref. 16 ). The high sequence conservation between the class I and II ARFs (>80%), their overlapping biochemical activities when overexpressed, and their similar expression pattern has hampered progress to unambiguously assign defined roles to the individual ARFs.
Here, we conducted a large-scale insertional mutagenesis screen in a near-haploid human chronic myeloid leukaemia cell line to identify genes essential for BFA-induced apoptosis and thereby uncovered C5orf44/TRAPPC13, and, unexpectedly, ARF4. Despite the previously reported redundancy between different ARF members, our study uncovers a role for ARF4 in response to BFA not shared with other ARF isoforms. We functionally dissected the mechanism of BFA resistance in ARF4-depleted cells and demonstrate that this occurs through upregulation of other ARF members such as ARF1 and ARF5, and also requires GBF1. Furthermore, we uncovered a signalling module involving the CREB3 transcription factor and ARF4 whose expression levels correlate with Golgi integrity and might be part of a Golgi stress response. The physiological importance of these results is indicated by additional findings revealing that ARF4 is critical for pathogenicity of C. trachomatis and S. flexneri, which infect millions each year.
RESULTS

ARF4 depletion provides resistance to several Golgi stress agents
To identify genes involved in BFA-induced toxicity, we employed a gene trap (GT)-based insertional mutagenesis approach using the near-haploid KBM7 cell line 17, 18 . A heterogeneous population of approximately 100 million cells containing random knockout mutations was assessed for their ability to resist cell death induced by chronic (3 weeks) BFA treatment. BFA-resistant GT cells were pooled at the end of the experiment, their DNA isolated, and the individual insertions mapped to the genome using deep sequencing 19 . Two genes were enriched for GT insertions and associated with highly significant P values (Fig. 1a) : 37 GTs mapped to ARF4 (P < 8.39 × 10 −110 ) and 12 to C5orf44/TRAPPC13 (P < 7.86 × 10 −29 ). For the remainder of this article we will focus on ARF4, and findings related to C5orf44/TRAPPC13 will be described elsewhere.
Using several lentivirally transduced short hairpin RNAs (shRNAs) targeting ARF4, resistance to BFA was recapitulated in multiple cell lines including A549, HeLa, HT29, U251, PANC1, PC3, DU145, 786-0, MCF7 and MDA-MB231, thereby revealing an essential, conserved role for ARF4 in mediating BFA susceptibility ( ). Loss of ARF4 did not significantly alter proliferation or cell cycle phases relative to control cells (data not shown). To elucidate whether loss of ARF4 protects against other Golgi-disrupting agents, cells were treated for several days with golgicide A (GCA) or Exo1. As with BFA treatment, ARF4 knockdown cells were largely protected from undergoing apoptosis when exposed to GCA or Exo1 in comparison with control cells (Fig. 1c) . ARF4-depleted cells were, however, not resistant to other ER stress inducers including tunicamycin, thapsigargin or A23187, pointing to a specific function of ARF4 in the secretory pathway ( Supplementary Fig. S1b ).
The ARFs may act pairwise or in a sequential manner to reinforce or diversify secretory transport processes, because earlier RNA interference (RNAi) studies revealed that only combinatorial knockdown of different ARF isoforms caused aberrations in the secretory pathway [20] [21] [22] .
The finding that ARF4 loss alone was sufficient to render cells BFA-resistant was therefore not anticipated and hinted at a discrete role for ARF4 not shared with other ARFs. Our screen recovered GT integrations only in ARF4 but not in any other ARF locus. To rule out the possibility that all ARFs but ARF4 were false negatives either due to essentiality or to potential limitations associated with our screening approach such as insertion site preferences of the retroviral GT vector, we depleted several cell lines individually of each ARF family member by transduction with lentiviral shRNAs. Reassuringly, when we knocked down ARF5, the other class II ARF, in HeLa or PANC1 cells, no BFA-resistance was observed. Instead, these cells were more sensitive to BFA than controls ( Supplementary Fig. S1c,d ). Lentivirus-mediated depletion of ARF1 using multiple independent shRNAs caused lethality in A549, HeLa, MCF7, PC3, HEK293T and PANC1 cells, indicating that ARF1 function is essential (data not shown). We therefore repeated the infection with a several-fold lower virus titre to generate cells with reduced ARF1 expression that was compatible with survival. Reminiscent of ARF5 loss of function cells, ARF1-depleted cells were hypersensitive to BFA treatment (Fig. 4b , vector control panel). Therefore, loss of ARF4 protects against whereas loss of ARF1 or ARF5 sensitizes to BFA, suggesting a unique function for ARF4 in mediating BFA susceptibility. Given the protection of ARF4 knockdown cells from the cell-lethal effects of lower BFA concentrations, Golgi morphology was assessed next by immunofluorescence microscopy. No obvious difference was detected between control and ARF4 knockdown cells under untreated conditions when stained for Giantin, GM130 or GBF1 ( Fig. 2a and Supplementary Fig. S2a ). BFA treatment of cells infected with control shRNAs promoted a diffuse appearance of the Golgi markers throughout the cytoplasm, indicative of Golgi disassembly. Strikingly, most cells depleted of ARF4 exhibited a normal Golgi morphology after BFA application similar to the Golgi staining pattern in untreated conditions ( Fig. 2a and Supplementary Fig. S2b ). In agreement with these results, general protein secretion was not inhibited by BFA in cells lacking ARF4 compared with control cells (Fig. 2b) . Moreover, haemagglutinin (HA) glycan maturation of cells infected with influenza A virus or class I MHC receptor trafficking was blocked in BFA-treated control cells but not in ARF4 knockdown cells ( Fig. 2c and Supplementary Fig. S2c ). Thus, the integrity and functionality of the Golgi and secretory pathway following treatment with low BFA concentrations are preserved in ARF4-depleted cells. Under acute short-term treatment with high BFA concentrations, however, GBF1 staining was dispersed in ARF4 knockdown cells, as in the controls, indicative of a disrupted Golgi (Supplementary Fig. S2d ).
Compensatory ARF upregulation in cells with downregulated ARF4 function
Expression of activated forms of ARF1 or Rab1 and increased GBF1 or BIG2 expression were described to protect against BFA-induced Golgi disintegration [23] [24] [25] [26] [27] . However, no obvious alterations in expression levels of GBF1, BIG1 and BIG2, several Golgi-matrix proteins (GM130, GRASP65, Giantin, Golgin-84) or Rab1b were detected under basal conditions in ARF4 knockdown protein lysates (Fig. 3a,b and data not shown). The ARF1 monoclonal 1D9 antibody is a pan-ARF antibody recognizing ARF1, ARF3, ARF5, ARF6 and, to lesser extent, ARF4. Using this antibody, increased expression was observed in multiple cancer cell lines including U251, PC3, DU145, HT29, 786-0, 
Figure 1
Loss of ARF4 provides resistance to several Golgi-disrupting agents. (a) Mutagenized KBM7 cells were grown for 3 weeks in the presence of 50 ng ml −1 (180 nM) BFA, after which genomic DNA of the surviving cells was isolated and the GT insertion sites determined by deep sequencing and alignment to the genome. The number of independent insertions per gene was determined (represented by the circle size) and compared with that of an unselected mutagenized cell population from which enrichment scores (P values) were derived (y axis). GT insertions were ordered along the x axis on the basis of their chromosomal position. The two genes that were most enriched compared with an untreated control data set were ARF4 (37 GTs; P < 8. MDA-MB231, PANC1 and HeLa cells (Fig. 3a-c , and data not shown).
We also tested a panel of additional ARF antibodies that discriminate ARF isoforms. Enhanced ARF1, ARF3 and ARF5 expression but not ARF6 was detected when ARF4 was lost (Fig. 3a,b) . To assess whether increased ARF levels translated into activity changes, an ARF-pulldown assay was employed 28 . In agreement with the observed pan-ARF expression changes, ARF activity increased 1.5-2-fold in untreated or BFA-treated HeLa and PC3 ARF4 knockdown cells compared with control cells (Fig. 3a,b) .
On the basis of these findings, we surmised that increased ARF1, ARF3 and ARF5 expression might play critical roles in ARF4-depleted cells to endow them with the capacity to withstand BFA toxicity. Accordingly, lentivirus-mediated stable overexpression of either ARF1 or ARF5 alone but not ARF4 was sufficient to enhance cellular survival of A549 cells in the presence of BFA (Fig. 4a) . We next examined whether blocking ARF1, ARF3 or ARF5 function in cells without ARF4 might reverse BFA resistance. To test this we re-infected stable ARF4 knockdown or control cells with lentiviral ARF1, ARF3 or ARF5 shRNA vectors carrying different antibiotic markers to select for double-knockdown cells. ARF1-ARF4 double-knockdown and control cells were then grown in the presence or absence of BFA for several days, and their survival ratio was calculated. Strikingly, whereas ARF4 knockdown cells re-infected with LUC or RFP shRNAs were BFA-resistant, ARF1-ARF4 double-knockdown cells exhibited up to 60% lower survival comparable to cells that had been successively infected with two innocuous shRNAs (that is, vector control + LUC shRNA or RFP shRNA; Fig. 4b ). We also found that ARF4 ARF5 doubleknockdown cells had a lower survival ratio compared with ARF4 knockdown cells re-infected with control shRNAs ( Supplementary  Fig. S3a ). Unlike ARF1-ARF4 or ARF4 ARF5 co-depletion, survival of BFA-exposed ARF3 ARF4 double-knockdown cells did not differ from ARF4 knockdown cells infected with control shRNAs, suggesting Influenza-derived HA-trafficking through the secretory system was analysed after a pulse of radioactive-labelled methionine/cysteine followed by a chase with cold methionine/cysteine. The results show that HA glycan-processing is not disrupted in the presence of BFA in cells without ARF4. HA0 is the full-length HA that forms in the ER and trafficks through the Golgi. HA1 refers to HA that has reached the cell surface and is cleaved by trypsin added to the chase media. The experiment was performed twice. See Methods for further details.
that BFA protection against BFA occurs at the early Golgi but not at the trans-Golgi network where ARF3 localizes 29 ( Supplementary  Fig. S3b ). GBF1 acts as a GEF for several ARF isoforms including ARF1, ARF4 and ARF5 and is the rate-limiting factor to control their activity at the ERGIC and early Golgi 30 . Downregulation of GBF1 therefore inhibits ARF activity, and GBF1 depletion should be functionally equivalent to ARF1 and ARF5 loss. Cells infected with both a control and a GBF1 shRNA showed a similar survival ratio to cells infected with control shRNAs after BFA treatment, unlike ARF4 LUC double-knockdown cells that were largely resistant to
Vehicle BFA. Strikingly, ARF4 GBF1 double-knockdown A549 and HeLa cells became BFA-sensitive and exhibited the same survival as single GBF1 knockdown cells (Fig. 4c and data not shown). In summary, resistance of ARF4-depleted cells is abrogated following ARF1, ARF5 or GBF1, but not ARF3 co-depletion, demonstrating that BFA resistance of ARF4 knockdown cells depends on compensatory accumulation of other ARF isoforms or GBF1. When double-knockdown protein lysates were analysed for ARF4 expression, we found that loss of ARF1 or GBF1 entailed the re-emergence of ARF4 expression both in vector control and ARF4-shRNA-infected cells, indicative of a coordinated regulation of their expression (Fig. 4b ,c, see also Supplementary Fig. S7 ).
Golgi stress causes ARF4 induction mediated through CREB3
During this study we made the observation that most of the analysed cancer cell lines treated with BFA upregulated ARF4 levels ( Fig. 5a ). In addition, treatment with GCA, Exo1 or monensin also enhanced ARF4 expression in a manner independent of general ER stress induction, because GRP78 or CHOP levels were unchanged in Exo1-treated cells, and because tunicamycin or thapsigargin had minimal effects on ARF4 levels ( Fig. 5b,c) . Interestingly, thapsigargin treatment was reported to induce Golgi fragmentation, which might explain the slightly increased ARF4 levels 31 . To investigate whether ARF4 upregulation could be prevented by antagonizing BFA-induced Golgi dispersal, cells were simultaneously treated with BFA and H-89 or forskolin, respectively. H-89 is a non-selective, cell-permeable protein kinase inhibitor that sustains Golgi morphology and ARF1-GTP levels in the presence of BFA, and forskolin acts through a BFA-detoxification mechanism and accordingly renders cells less susceptible to BFA (refs 2,32,33) . Indeed, H-89 or forskolin mitigated ARF4 upregulation in a dose-dependent manner when cells were co-treated with BFA, which was paralleled by UPR marker expression (Fig. 5d,e) . ARF4 levels therefore correlate with Golgi integrity exhibiting low ARF4 expression under basal conditions but increased levels following certain stress conditions that impinge on Golgi homeostasis.
Quantitative real-time PCR (qPCR) analysis revealed that BFA treatment induces ARF4 transcription (Fig. 6a) . Although all other ARF genes trended towards increased expression following BFA exposure, only ARF1 reached significance, however, to a lower magnitude than Vector control
Second shRNA: ARF4. In addition to the ARF genes, transcript levels of the three GEFs BIG1, BIG2 and GBF1 became upregulated in the presence of BFA (Supplementary Fig. S4a ). As shown earlier for GBF1, we also observed a concomitant increase in protein levels following BFA treatment (Fig. 5a ). ARF4 increase was prevented by co-treatment of cycloheximide and BFA ( Supplementary Fig. S4b ). Together, this indicates that ARF4 expression is controlled through new messenger RNA and protein production. It was reported that phorbol 12-myristate 13-acetate (PMA) treatment induces ARF4 expression, in a manner dependent on a CREB3 isoform lacking the transmembrane domain 34 . CREB3 is a basic leucine zipper (bLZIP) ER-bound transcription factor that is proteolytically cleaved following activation in the Golgi apparatus by site-1 protease (S1P) and site-2 protease (S2P), and then enters the nucleus where it binds as a homodimer to canonical cyclic-AMP-response elements (CREs) to enhance transcription of its targets 35 . How ARF4 levels are regulated following BFA treatment is unknown. To examine whether BFA-induced ARF4 expression requires CREB3, several cell lines were infected with CREB3 shRNAs to deplete CREB3. BFA-treated CREB3 knockdown A549 cells exhibited substantially reduced ARF4 levels paralleled by GRP78 and CHOP downregulation when compared with control cells (Fig. 6b) . Similar results were obtained in PC3, PANC1 or = 36 nM and 50 ng ml −1 = 180 nM); lanes 4-6: tunicamycin (TM; used at 100 ng ml −1 (119 nM), 500 ng ml −1 (597 nM) and 2 mg ml −1 (2.39 µM); lanes 7-9: thapsigargin (TG; used at 10, 100 and 500 nM); lane 10: GCA (used at 5 µM). Western blots are representative of two independent experiments. (d,e) Co-treatment of A549 or HeLa cells with BFA and increasing amounts of H-89 or forskolin, two compounds that antagonize BFA-induced Golgi dispersal, mitigates upregulation of ARF4 and UPR parameters. The experiment was repeated twice with qualitatively similar results.
MDA-MB231 cells, demonstrating that CREB3 is a conserved mediator of the cellular response to BFA (Fig. 6c) . Further strengthening this link, we found that CREB3 downregulation promoted ARF1 induction ( Supplementary Figs S4d and S6f) . Hence, CREB3 knockdown mirrors loss of ARF4 function. Akin to BFA treatment, CREB3 is also required for ARF4 induction in response to GCA, Exo1 and monensin ( Supplementary Fig. S4d ). These treatments also activated and redistributed ER-localized CREB3 into the nucleus ( Supplementary  Fig. S5a ). Moreover, proteolytic activation of CREB3 and ARF4 upregulation is dependent on S1P, because S1P inhibitors (AEBSF and PF-429242) lower CREB3 stabilization and ARF4 expression in response to BFA, GCA, Exo1 and monensin ( Supplementary Fig. S5b,c) . Western blot analysis also revealed that in the presence of BFA, CREB3 levels increase beyond the weakly detectable levels observed under basal conditions presumably due to its inherent instability 36, 37 (Fig. 6b,c) . To assess whether loss of CREB3 alters cellular BFA susceptibility, we cultured the knockdown cells in the absence or presence of the drug. As for ARF4-depletion, CREB3 knockdown cells showed enhanced resistance to BFA relative to control cells (Fig. 6d) . Next, we monitored the effects of CREB3 overexpression on ARF4 levels and BFA sensitivity shRNAs. Error bars of the controls represent s.e.m. Treatment durations were 3 and 4 days for A549 and PC3 cells, respectively. (e) Stable CREB3 overexpression is sufficient to elevate endogenous ARF4 levels in PANC1 or HEK293T cells. Following overexpression, two bands could be detected by western blotting when antibodies against the Flag-epitope or endogenous CREB3 were used. The predominant band detected in most cell lines when probed for endogenous CREB3 is the upper band (relative molecular mass of approximately 50,000 (M r 50K, corresponding to the full-length form), and a lower band (approximately M r 35K-40K) is occasionally discernible and might represent S1P/S2P-mediated cleavage products 46 . The asterisk denotes a nonspecific band. Western blots are representative of two independent experiments. (f) Increased BFA susceptibility of stable cell lines overexpressing CREB3. P values for PANC1 cells were P < 0.002 for both BFA concentrations (n = 4 wells), and treatment duration was 4 days. For HEK239T cells (n = 4 wells) P = 0.045 and P = 0.001 using 30 ng ml −1 and 40 ng ml −1 BFA, respectively (Student's two-tailed t -test). All error bars represent s.d. The asterisk denotes a nonspecific band.
by establishing stable cell lines overexpressing epitope-tagged CREB3. Despite only modest CREB3 overexpression levels, ARF4 induction was readily discernible whereas other ARF isoforms were slightly but reproducibly downregulated (Fig. 6e and Supplementary Fig. S4c ). CREB3 overexpression sensitized cells to undergo apoptosis in response to BFA, correlating with higher ARF4 levels and a concomitant decrease in the amount of other ARFs (Fig. 6f) .
We investigated whether the increased BFA sensitivity of ARF1 or GBF1 knockdown cells and re-emergence of ARF4 expression in these cells (Fig. 4 ) might be associated with altered CREB3 localization. To this end, A549 GBF1 or ARF1 knockdown and control cells were transfected with a Flag-CREB3 overexpression vector and CREB3 localization was examined by immunostaining. As for BFA treatment, ARF1 knockdown or GBF1 knockdown resulted in CREB3 accumulation in the nucleus, presumably caused by partial Golgi fragmentation providing a possible explanation for enhanced ARF4 expression ( Supplementary Fig. S7 ).
Loss of ARF4 protects against propagation of several pathogens
Whereas BFA chemically induces Golgi dispersal, two intracellular bacterial pathogens, C. trachomatis and S. flexneri, naturally subvert host trafficking pathways to acquire lipids and disrupt cytokine secretion by inducing Golgi fragmentation 38 . We reasoned that infection-mediated Golgi disruption was similar to BFA treatment, and therefore ARF4 knockdown cells may prevent efficient pathogen growth. When we investigated the effects of Chlamydia infection on ARF4, no appreciable upregulation was detected in control cells. A slight boost in ARF4 expression was detected in ARF4 knockdown cells (Supplementary Fig. S6a ). We investigated whether the life cycle of either Chlamydia or Shigella might be affected by ARF4 loss because its depletion protected against pharmacological compound-induced Golgi disruption. We infected control and ARF4 knockdown HeLa cells with Chlamydia or Shigella, and growth was assessed at various time points after infection. For both pathogens, no significant replication level differences between control and ARF4-deprived cells were detected early, indicating that invasion of ARF4-depleted cells is not disrupted. However, we noted defects in persistence/growth for both pathogens late during infection. At 48 h post-infection Chlamydia replication was reduced by about 40-60% with two independent shRNAs against ARF4 using a qPCR assay (Fig. 7a) . As Chlamydia must complete a biphasic life cycle to invade new host cells, we examined the production of infectious progeny in control or ARF4-deprived cells and found that depletion inhibited the production of inclusion-forming units (IFUs; Fig. 7b ). We noted that 8 h following Shigella infection there was a twofold reduction in intracellular bacteria in ARF4 knockdown cells, a phenotype that became even stronger after 20 h when intracellular persistence was reduced about 70-100-fold (Fig. 7d) . Both Shigella and Chlamydia directly target ARF1-dependent pathways during infection 39 . We also examined the growth of the pathogen Salmonella enterica serovar typhimurium, which does not fragment the Golgi during intracellular replication. However, no survival defect was observed in ARF4-depleted cells when compared with control cells (data not shown). This shows that restriction of both Chlamydia and Shigella, two pathogens with distinct intracellular lifestyles, may be due to defects in Golgi fragmentation and not pleiotropic effects of ARF4 depletion.
We further examined the mechanisms driving resistance to Chlamydia infection following a reduction in ARF4 levels. One requirement for Chlamydia propagation is sphingomyelin, which is synthesized from ceramide produced in the ER, and actively acquired by the bacteria 40 . Blocking Golgi fragmentation in infected cells through chemical inhibition prevents efficient uptake of ceramide into the inclusion 38 . We assessed the consequences of adding fluorescent NBD-C 6 -ceramide to control and ARF4 shRNA-infected HeLa cells. The results show a significant reduction of intracellular ceramide accumulation in ARF4 knockdown cells (Fig. 7b, right lower panel) , raising the possibility that sphingolipid transfer to the inclusion may be compromised. Using immunofluorescence microscopy we assessed the Golgi morphology of Chlamydia-infected cells. GM130 staining was more discernible and pronounced in ARF4 knockdown cells with a more compact and dense appearance, whereas RFP shRNA cells exhibited a thinner structure and more dispersed Golgi elements (ministacks; Supplementary Fig. S6b ). Complementary to the ARF4 loss of function phenotype, ARF4 but not ARF1 or ARF5 overexpression, enhanced Chlamydia replication (Fig. 7c) .
Previous work showed that loss of ARF1 or GBF1 enhances Chlamydia infection, suggesting that enhanced ARF activity limits replication 41, 42 . We reasoned that the compensatory increase in ARF1 and/or ARF5 may underlie the resistance of ARF4 knockdown cells to Chlamydia growth, as for BFA resistance. To test this we established the corresponding double-knockdown HeLa cells and examined whether increased resistance to Chlamydia is affected in cells co-depleted of ARF4 and other ARF isoforms or GBF1. As we were not able to establish ARF1-ARF4 double-knockdown HeLa cells owing to lethality, our analysis was restricted to the remaining ARF4 double-knockdown combinations. In line with our earlier results, the absence of both GBF1 and ARF4 enhanced the production of infectious Chlamydia when compared with control ARF4 double-knockdown cells (ARF4 shRNA GFP shRNA and ARF4 shRNA RFP shRNA). Combinatorial loss of both ARF4 and ARF5 led to a slight recovery of bacterial growth, but not to the levels of GBF1, suggesting an important role for ARF1 in bacterial growth. ARF3 depletion was without effect ( Supplementary Fig. S6c,d ). These data show that bacterial restriction in ARF4 knockdown cells is driven by the compensatory upregulation of other ARFs, similar to BFA treatment.
As CREB3 regulates ARF4 expression and sensitivity to BFA (Fig. 6) , we also assessed its effects on the survival of Chlamydia and Shigella. HeLa CREB3 knockdown cells were subjected to the same pathogen infection assays as described above. We found that these cells were several-fold more resistant to both pathogens relative to controls (Supplementary Fig. S6e ). Interestingly, under basal conditions we noted higher expression of ARF1 in CREB3 knockdown cells, consistent with the upregulation and pathogen restriction seen in ARF4 knockdown cells (Supplementary Fig. S6f) . Thus, these data suggest that a CREB3-ARF4 signalling pathway mediates the survival response to a number of pharmacological Golgi-perturbing agents and certain Golgifragmenting pathogens.
DISCUSSION
We have identified ARF4, one of the five human members of the ARF family of small G proteins, in a loss of function viability screen in human cells for genes providing resistance to BFA. The ARF family members are regarded as providing overlapping functions such that depletion of any single ARF does not cause discernible secretory trafficking pathway alterations. In ref. 20 , siRNA treatment of HeLa cells was used to deplete ARFs individually or in pairwise combinations, but no effects on the levels of other ARF isoforms were reported. We, however, found increased expression of other ARFs after lentiviral-mediated downregulation of ARF4. A possible explanation could be differences in the ARF knockdown levels achieved in each respective study. Here, we have shown that ARF4 knockdown is sufficient to make cells resistant to BFA, GCA or Exo1, which is the opposite phenotype compared with ARF1-or ARF5-depleted cells. Cells lacking ARF4 preserve Golgi integrity and function even in the presence of BFA, and we found upregulated ARF1, ARF3 and ARF5 levels accompanied by increased pan-ARF activity in these cells. Furthermore, we discovered that BFA exposure increased the levels of GBF1, BIG and BIG2. Together, these findings suggest that the combination of enhanced ARF and ARF-GEF levels in ARF4-depleted cells enables them to cope with toxic BFA concentrations, allowing their secretory pathway activity to be sustained and hence their survival in the presence of the drug. In agreement with this model, downregulation of ARF1, ARF5, and GBF1, but not ARF3, in ARF4 loss of function cells restored BFA sensitivity. In addition to conferring resistance to several Golgi-disassembling agents, we found that ARF4 and CREB3 depletion protected against intracellular growth of two pathogenic bacteria, C. trachomatis and S. flexneri, that cause Golgi fragmentation following infection. It is likely that intracellular trafficking pathways important for bacterial nutrient supply or to escape host defence mechanisms are impaired in these cells 38, 43 . For Chlamydia, transport of sphingolipids or cholesterol into the inclusion, which depends on Golgi fragmentation, could be inhibited when ARF4 is absent (ref. 38) . Chlamydia and Shigella infect millions every year yet no effective vaccine is available 44, 45 . In light of the increased occurrence of antibiotic-resistant Chlamydia and Shigella strains and the fact that cells without CREB3 or ARF4 restrict bacterial growth, inhibitors that target CREB3/ARF4 functions may become a new treatment option to combat a subset of intracellular infections. Altogether, these results suggest that inhibition of ARF4 or CREB3 could prove beneficial in several disease settings to restrict the pathogenicity of intracellular pathogens.
A further unanticipated finding of this study was that incubation of cells with BFA induced ARF4 expression through CREB3. CREB3 belongs to a family of bZIP ER membrane-bound transcription factors that also includes OASIS (CREB3L1), BBF2H7 (CREB3L2), CREBH (CREB3L3) and CREB4 (CREB3L4/AIbZIP/Tisp40). This family is also related to ATF6α/β, one of the three main proximal ER stress transducers, and furthermore shares the same mechanism of activation. The functions of CREB3 are ill defined, and whereas several other of the five CREB3-like transcription factors are activated in response to ER stress and contribute to diversification of the UPR in a cell-type specific manner, there is some debate regarding whether CREB3 is induced under ER stress conditions [46] [47] [48] [49] [50] [51] . ARF1 or GBF1 depletion by RNAi caused ARF4 levels to rise, indicating that their levels are coordinately regulated (Fig. 4b,d ). GBF1 depletion causes relocation of S2P from the Golgi to the ER (ref. 52 ), and we demonstrate that inhibition of S1P alleviates CREB3 and ARF4 induction elicited by BFA treatment (Supplementary Fig. S5b,c) . Furthermore, we found that exogenous CREB3 expression in GBF1 knockdown and ARF1 knockdown cells leads to its nuclear relocation (Supplementary Fig. S7 ). Presumably full-length CREB3 is cleaved by S1P and S2P in GBF1 knockdown or ARF1 knockdown cells, thereby mimicking BFA treatment.
We extended the findings made with BFA to three other compounds compromising the Golgi-GCA, Exo1 and monensin-which all increased ARF4 expression, suggesting that its levels might parallel Golgi integrity or Golgi stress induction. Treatment with these chemicals leads to proteolytic CREB3 activation through S1P and S2P followed by its nuclear accumulation (Supplementary Fig. S5a ). At present we can only speculate as to which specific Golgi stress stimulus causes ARF4 induction. GCA has a mode of action comparable to BFA by inhibiting ARF1-GBF1 function and potentially other ARFs causing COPI vesicle coat dissociation from Golgi membranes 53, 54 . The Golgifragmenting effects of Exo1 might be promoted by GTP hydrolysis on all Golgi-localized ARF members, thereby mimicking reduced ARF activity 55 . The cationic ionophore monensin promotes H + /Na + exchange, which leads to alkalization of the Golgi lumen causing osmotic swelling mainly in late Golgi and post-Golgi/endosomal compartments and a block in anterograde and retrograde transport [56] [57] [58] . Increased ARF4 expression therefore might be related to loss of ARF1 from Golgi membranes and/or decreased ARF1 activity leading to defects in Golgi integrity.
Another question is what the purpose of ARF4 upregulation during Golgi stress might be. Whether enhanced ARF4 expression as a result of Golgi stress treatments represents a cellular attempt to boost Golgi capacity and thereby to regain sufficient secretory pathway function in the presence of BFA, or conversely whether ARF4 induction initiates a so far uncharacterized apoptotic program to eliminate cells with irreparable Golgi damage, is not known. It could also be that increased ARF4 levels negatively regulate the activities of Golgi-protective ARFs such as ARF1. Notwithstanding the precise signalling mechanisms downstream of ARF4, we speculate that the Golgi apparatus might actively sense certain stress stimuli and relay a signal to the nucleus to induce factors critical for the re-establishment of Golgi homeostasis or to trigger pro-apoptotic events if the stress is insurmountable. The proposed signalling pathway could therefore be viewed as a Golgi stress response comparable to the unfolded protein response that is initiated at the ER (refs 59,60) . How Golgi stress might be sensed, and what the stress signals are, remains to be further investigated.
Golgi fragmentation is a pathological feature of several neurodegenerative diseases including amyotrophic lateral sclerosis, Alzheimer's, Parkinson's and spinocerebellar ataxia type 2 (refs 31,61-63) and is also observed in patients with Niemann-Pick type C disease 64 . In addition, several bacteria and viruses induce Golgi disassembly 65 . It is therefore possible that these pathologies are associated with Golgi stress induction. Elucidating the components acting in this proposed Golgi stress signalling network might thus be valuable in identifying new treatment options for neuronal disorders, cancer, or pathogen-induced disease states.
METHODS
Methods and any associated references are available in the online version of the paper. including extraction of DNA and determination of GT insertion sites, proliferation assays, immunofluoresecence microscopy, and lentivirus production has been published previously 17, 19 . Briefly, cell viability assays were performed either using a Z2 Coulter counter apparatus (Beckman Coulter) for direct cell number counts (cells with diameters between 10 and 30 µm were counted), or using the CTG assay (Promega). IF images were generally acquired with an epifluorescence microscope (Zeiss Axiovert 200 M, ×63 magnification) equipped with a Zeiss AxioCam camera. To acquire the images shown in Supplementary Fig. S6b , a Zeiss LSM 710 NLO laser scanning confocal microscope was used. For western blotting, proteins were resolved on 4-12% NuPAGE Novex gradient Bis Tris gels (Invitrogen) and transferred onto PVDF membranes (Immobilon). IgG-HRP-coupled secondary antibodies (Santa Cruz Biotechnology) for immunoblotting were used at 1:5,000 in 5% milk/PBS-T for 1 h incubation at room temperature. Proteins bands were visualized with Western Lightning chemiluminescence (ECL)/plus-ECL reagent (Perkin-Elmer).
Cell culture. All cell lines described with the exception of KBM7 cells were grown in standard Dulbecco's modified Eagle's medium (DMEM) with 10% heat-inactivated fetal serum (IFS) in the presence of 250 units ml −1 penicillin and 250 µg ml −1 streptomycin. KBM7 cells were grown in Iscove's modified Dulbecco's medium (IMDM) supplemented with antibiotics.
Densitometric analyses. Quantification of western blots presented in Fig. 3b to determine normalized ARF-GTP levels was done using ImageJ analysis software (densitometry measurement tool). In Fig. 3b , pan-ARF bands were normalized to PAR-4 protein lysate levels, which remain unchanged in response to brefeldin A (BFA) treatment.
Bacterial strains and media. S. flexneri serovar 2a WT strain 2457T, S. enterica serovar typimurium strain SL1344 and C. trachomatis serovar L2 434/Bu were used in this study and have been previously described [66] [67] [68] .
Chlamydia quantitative PCR and inclusion-forming unit assays. To assess the levels of C. trachomatis present, we used a previously established qPCR method 69 . Briefly, we isolated nucleic acid from infected cells using the DNeasy kit (Qiagen). Chlamydia 16S DNA was quantified by qPCR on an ABI Prism 7000 sequence detection system using primer pairs and dual-labelled probes. Using standard curves from known amounts of Chlamydia, the levels of 16S DNA per well were calculated. For inclusion-forming unit (IFU) experiments, control cells or ARF4 knockdown cells were seeded at a density of 5 × 10 4 into 24-well plates in triplicate. Cells were infected the following day with 5 × 10 4 IFUs of C. trachomatis for 48 h. Cells were subsequently lysed and diluted 1:1,000 or 1:10,000 and re-seeded into 24-or 96-well plates containing 10 4 wild-type HeLa cells. Twenty-four hours following infection, cells were fixed with ice-cold methanol for 30 min. Cells were washed two times with PBS containing 0.1% Tween. Cells were then stained using DAPI and an antibody against C. trachomatis MOMP. Cells were quantified by fluorescence microscopy and the mean number of IFUs produced by control cells and ARF4 knockdown cells for each well was calculated.
Gentamicin protection assay. Fifty thousand control or ARF4 knockdown cells were seeded in 24-wells plates in triplicate. Cells were infected with S. flexneri or S. typhimurium by centrifuging exponential-phase bacteria diluted in PBS onto semi-confluent monolayers of cells at a multiplicity of infection (MOI) of 1:1 at 700g for 10 min. The cells were subsequently incubated for 20 min at 37 • C and 5% CO 2 , washed three times with PBS, and placed in medium containing gentamicin (25 µg ml −1 ) to kill extracellular bacteria. To assess intracellular bacterial number, the cells were then incubated for indicated amounts of time in media containing gentamicin, washed three times with PBS, and lysed in 0.1% sodium deoxycholate/PBS. Cell lysates were then plated on tryptic soy agar (TSA) or LB plates, and colony-forming units were counted after overnight incubation at 37 • C.
NBD C 6 -ceramide pulse labelling. Control or ARF4 shRNA cells were infected with C. trachomatis at an MOI of 5 for 20 h. The medium was aspirated and replaced with PBS containing NBD-ceramide (Invitrogen) and placed at 37 • C for 1 h. Cells were then washed with PBS and placed in fresh medium to allow back exchange of fluorescent ceramide. Five hours following pulse labelling, the medium was removed and replaced with PBS. Plates were then read using a SpectraMax M2 plate reader with an excitation/emission of 466/536 nm.
Virus infections and pulse-chase experiments. HeLa cells were grown in 10 cm culture dishes and infected with wild-type WSN influenza A at an MOI of 0.5 for 4 h in DMEM supplemented with BSA and 1 µg ml −1 TPCK-treated trypsin. Cells were collected and resuspended in methionine-and cysteine-free DMEM and starved for 45 min at 37 • C followed by a 10 min pulse labelling with Following BFA treatment, labelling medium was replaced with fresh medium with or without 50 ng ml −1 BFA. At indicated time points, medium was collected, total protein precipitated using trichloro acetic acid (TCA) and subjected to SDS-PAGE to resolve total secreted proteins.
Quantitative real-time PCR. Cells were grown in 6 cm dishes, and mRNA was isolated using the RNeasy Plus Mini kit (Qiagen). One microgram of total RNA was used for the reverse transcription reaction using Oligo dT primers and Superscript III (Invitrogen Life Sciences). Complementary DNA was diluted 1:15 after reverse transcription for subsequent use for qPCR. SYBR Green PCR master mix (Applied Biosystems) was used and reaction volume was 10 µl per qPCR reaction (384-well plate run on an ABI 7900 machine). Three biological replicates were analysed per genotype and condition, and two technical replicates were run per biological replicate for calculating the mean Ct values.
VHS-GAT pulldown assay. ARF activity was measured using an ARF pulldown assay essentially as described earlier 70 . GST-VHS-GAT (VHS-GAT from GGA3) was bacterially expressed, and the cell pellet was spun down at 4000 r.p.m. (JA-10 rotor, Beckman Coulter). The cell pellet was lysed by sonication in 20 ml lysis buffer (40 mM HEPES at pH 7.4, 150 mM NaCl, 2 mM EDTA, 1 µM dithiothreitol and protease inhibitor cocktail (Roche)). The bacterial cell lysate was then centrifuged for 30 min at 20,000 r.p.m. (JA-20 rotor, Beckman Coulter), and glutathione agarose beads (Thermo Scientific) that had been washed two times with PBS and once with bacterial lysis buffer were added to the bacterial supernatant for 1 h to bind GST-VHS-GAT to the beads. Between 750 µg and 1.5 mg total human cell protein extracts (PC3 or HeLa lysed in 1% NP40 lysis buffer) was combined with 60 µl glutathione agarose-GST-VHS-GAT slurry and rotated for 2 h at 4 • C for ARF pulldown. Immunoprecipitates were washed three times in 1% NP40 lysis buffer before elution in 50-60 µl 2X sample buffer and boiling for 3 min. Eluates were resolved on a 4-12% gradient Bis-Tris gel and probed with anti-ARF1(1D9) antibody (pan-ARF).
Antibodies and reagents. Primary antibodies: mouse anti-FLAG M2 (1:500, F1804/clone M2, Sigma-Aldrich), mouse anti-Myc (1:500, #2276/clone 9B11, Cell Signaling Technologies), mouse anti-GBF1 (1:1,000, #612116, BD Transduction Laboratories), rabbit anti-Giantin (1:3,000, ab24586, Abcam), rabbit anti-CREB3 (1:500, ab42454, Abcam), mouse anti-ARF1 1(1D9)/pan-ARF (1:500, NB300- 
FlagγTubulin
Flag-CREB3
Supplementary Figure 8 continued 
